Ibuprofen Versus Ketorolac for Pain Relief During Hysterosalpingogram
NCT ID: NCT05190341
Last Updated: 2024-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
12 participants
INTERVENTIONAL
2022-03-24
2024-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. After IRB approval, the research pharmacist will provide motrin and ketorolac in identical packets labeled 1-88, after receiving the randomization strategy/number set from the research monitor.
2. REI physician on the protocol will screen patient for inclusion/exclusion from study at new patient consult or at future follow up visit when need for HSG is decided.
3. If patient pt screens eligible, discuss study. If elects participation then consent patient and randomize to group.
4. At time of scheduling HSG, patient will need to remind nursing that they are in HSG study. Nursing should also have the list of patients to reference when scheduling HSGs. Patients in the study will need to check in at the REI clinic 70 minutes prior to HSG in order to take their meds 60 minutes prior to scheduled procedure time. At same visit, REI RN will perform urine pregnancy test as previously scheduled.
a. meds will be kept in a locked cabinet in the REI research office in opaque sealed envelopes.
5. Patient will then go check into Radiology for their HSG.
6. HSG will be performed per standard clinical protocol. The HSG will be performed by REI physicians and OB/GYN residents (who are rotating on REI), which are the current standard of practice.
7. A nurse or provider associated with the study will need to be at the HSG for the sole purpose of study assistance. The provider performing the HSG, the study personnel recording pain levels, and the fluro tech will not be aware of the type of pre-procedural medication the patient received. The nurse or provider of study personnel will do the following:
1. time the procedure from placement of speculum through deflation of catheter balloon and removal of catheter. Record time in seconds (can write mins:seconds and then convert later).
2. record who performed the procedure, if a tenaculum had to be used, and if an attending had to take over the procedure
3. help patient record pain scale marks on the VAS sheet at the designated time periods.
7\. For clarity- there will be at least three providers at each HSG for study enrolled patients.
1. A provider who does the HSG
2. A fluoro technician to capture fluoro images for teh HSG
3. A study affialitied person to record pain scores for patient as above 8. At the conclusion of study recruitment, the blinded researchers will gain access to the subject ID's cohort status (ibuprofen vs ketorolac), and study analysis will be undertaken.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
SUPPORTIVE_CARE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ibuprofen
Patients randomized to this arm will receive an identical capsule to the other patient arm, and receive 800mg ibuprofen 1 hour before HSG.
Ibuprofen 800 mg oral
1 hour before HSG
Ketorolac
Patients randomized to this arm will receive an identical capsule to the other patient arm, and receive 30mg ketorolac 1 hour before HSG.
Ketorolac 30mg oral
1 hour before HSG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ibuprofen 800 mg oral
1 hour before HSG
Ketorolac 30mg oral
1 hour before HSG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* premenopausal females age 18-45
* patients currently undergoing HSG as part of routine work-up for infertility or subfertility, - - patients with negative urine pregnancy test within 24 hours of the scheduled procedure
* patients having performance of HCG between menstrual cycle days 5-12n
Exclusion Criteria
* patients with history of previous HSG performed
* patients with contrast allergy or other contraindications to HSG
* patients with contraindications to NSAID use
* Patients with the following:
* unwilling to consent
* positive urine pregnancy test within 24 hours of the scheduled procedure
* active renal or hepatic disease
* chronic narcotic users
* use of pain medications within 12 hours of the scheduled procedure
* patients with chronic pain conditions (fibromyalgia, complex regional pain syndrome, etc.)
* patients with unknown uterine anatomical pathology
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Madigan Army Medical Center
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruce Pier
Role: PRINCIPAL_INVESTIGATOR
Madigan Chief of REI, Department of OBGYN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Madigan Army Medical Center
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
221063
Identifier Type: -
Identifier Source: org_study_id